TISIDB

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00048 Small cytokines (intecrine/chemokine)
Function	Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001667 ameboidal-type cell migration GO:0002237 response to molecule of bacterial origin GO:0002250 adaptive immune response GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002467 germinal center formation GO:0002518 lymphocyte chemotaxis across high endothelial venule GO:0002544 chronic inflammatory response GO:0002685 regulation of leukocyte migration GO:0002687 positive regulation of leukocyte migration GO:0002688 regulation of leukocyte chemotaxis GO:0002690 positive regulation of leukocyte chemotaxis GO:0002920 regulation of humoral immune response GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006959 humoral immune response GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0010594 regulation of endothelial cell migration GO:0010596 negative regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010633 negative regulation of epithelial cell migration GO:0010818 T cell chemotaxis GO:0010819 regulation of T cell chemotaxis GO:0010820 positive regulation of T cell chemotaxis GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030335 positive regulation of cell migration GO:0030336 negative regulation of cell migration GO:0030595 leukocyte chemotaxis GO:0031334 positive regulation of protein complex assembly GO:0032102 negative regulation of response to external stimulus GO:0032103 positive regulation of response to external stimulus GO:0032496 response to lipopolysaccharide GO:0033622 integrin activation GO:0033623 regulation of integrin activation GO:0033625 positive regulation of integrin activation GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033630 positive regulation of cell adhesion mediated by integrin GO:0033631 cell-cell adhesion mediated by integrin GO:0033632 regulation of cell-cell adhesion mediated by integrin GO:0033634 positive regulation of cell-cell adhesion mediated by integrin GO:0035754 B cell chemotaxis GO:0035766 cell chemotaxis to fibroblast growth factor GO:0035767 endothelial cell chemotaxis GO:0035768 endothelial cell chemotaxis to fibroblast growth factor GO:0035769 B cell chemotaxis across high endothelial venule GO:0040013 negative regulation of locomotion GO:0040017 positive regulation of locomotion GO:0042742 defense response to bacterium GO:0043254 regulation of protein complex assembly GO:0043542 endothelial cell migration GO:0044089 positive regulation of cellular component biogenesis GO:0044344 cellular response to fibroblast growth factor stimulus GO:0045765 regulation of angiogenesis GO:0045785 positive regulation of cell adhesion GO:0048247 lymphocyte chemotaxis GO:0048514 blood vessel morphogenesis GO:0048535 lymph node development GO:0050900 leukocyte migration GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0050922 negative regulation of chemotaxis GO:0051271 negative regulation of cellular component movement GO:0051272 positive regulation of cellular component movement GO:0051480 regulation of cytosolic calcium ion concentration GO:0055074 calcium ion homeostasis GO:0060326 cell chemotaxis GO:0070098 chemokine-mediated signaling pathway GO:0071774 response to fibroblast growth factor GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072676 lymphocyte migration GO:0072678 T cell migration GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090287 regulation of cellular response to growth factor stimulus GO:0090288 negative regulation of cellular response to growth factor stimulus GO:0090630 activation of GTPase activity GO:0098542 defense response to other organism GO:1901342 regulation of vasculature development GO:1901623 regulation of lymphocyte chemotaxis GO:1904847 regulation of cell chemotaxis to fibroblast growth factor GO:1904848 negative regulation of cell chemotaxis to fibroblast growth factor GO:2000146 negative regulation of cell motility GO:2000147 positive regulation of cell motility GO:2000401 regulation of lymphocyte migration GO:2000403 positive regulation of lymphocyte migration GO:2000404 regulation of T cell migration GO:2000406 positive regulation of T cell migration GO:2000544 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2001026 regulation of endothelial cell chemotaxis GO:2001027 negative regulation of endothelial cell chemotaxis
Molecular Function	GO:0001664 G-protein coupled receptor binding GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005539 glycosaminoglycan binding GO:0008009 chemokine activity GO:0008201 heparin binding GO:0017134 fibroblast growth factor binding GO:0019838 growth factor binding GO:0030545 receptor regulator activity GO:0030546 receptor activator activity GO:0031724 CXCR5 chemokine receptor binding GO:0031735 CCR10 chemokine receptor binding GO:0042379 chemokine receptor binding GO:0045236 CXCR chemokine receptor binding GO:0046982 protein heterodimerization activity GO:0048018 receptor agonist activity GO:0048020 CCR chemokine receptor binding GO:0048248 CXCR3 chemokine receptor binding GO:1901681 sulfur compound binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04062 Chemokine signaling pathway
Reactome	R-HSA-380108: Chemokine receptors bind chemokines R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CXCL13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CXCL13 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25533286	Breast Carcinoma	Promote immunity (infiltration)	IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.
17709502	B Acute Lymphoblastic Leukemia	Inhibit immunity (T cell function)	Here, we report that B-ALL CD23+CD5+ B cells produce IL-10 at high level, which can be further elevated by costimulation with CCL19 and CXCL13. CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a B cell-derived IL-10-dependent manner and requiring a cell-cell contact. IL-10 secreted from B-ALL CD23+CD5+ B cells in vitro impairs tumor-specific CTL responses of syngeneic CD8+ T cells. The impairment of cytotoxicity of syngeneic CD8+ T cells is escalated by means of CCL19/CXCL13-induced up-regulation of IL-10 from B-ALL CD23+CD5+ B cells.

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CXCL13 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CXCL13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.169	0.854
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.264	0.898
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.473	0.789
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.129	0.847
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.377	0.718
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.76	0.521
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	2.078	0.0282
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.972	0.188
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	2.329	0.131
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.965	0.222
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.646	0.793
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.872	0.0164

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CXCL13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL13. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CXCL13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CXCL13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CXCL13
Name	chemokine (C-X-C motif) ligand 13
Aliases	BLC; BCA-1; BLR1L; ANGIE; ANGIE2; B-cell chemoattractant; SCYB13; small inducible cytokine B subfamily (Cys- ......
Chromosomal Location	4q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CXCL13 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CXCL13